Accordingly, we recently developed a small peptide-targeted MRI contrast agent to noninvasively image fibronectin (FN), a classical mesenchymal marker expressed by post-EMT carcinoma cells, including TNBC cells. The gene discussed is FN1; the disease is carcinoma.